秦氟替索 | 55837-23-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻喃类
• 中文名称: 秦氟替索
• 英文名称: Teflutixol
• 英文别名: 2-{4-[3-(6-fluoro-2-trifluoromethyl-thioxanthen-9-yl)-propyl]-piperazin-1-yl}-ethanol；2-trifluoromethyl-6-fluoro-9-(3-(4-(2-hydroxyethyl)-piperazine-1-yl)propyl)-thixanthene；2-[4-[3-[6-fluoro-2-(trifluoromethyl)-9H-thioxanthen-9-yl]propyl]piperazin-1-yl]ethanol
• CAS: 55837-23-5
• 化学式: C₂₃H₂₆F₄N₂OS
• 分子量: 454.532
• InChiKey: BJWAPFORUPUXRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Conjugated psychotropic drugs and uses thereof
  申请人：——

  公开号：US20040242570A1

  公开（公告）日：2004-12-02

  Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.

  本发明揭示了精神药物和有机酸的新型化学结合物，其在治疗精神病和/或增生性疾病和疾病以及作为化学增敏剂中的应用，所述的有机酸被选择用于减少由精神药物引起的副作用和/或发挥抗增殖活性。同时，本发明还揭示了这些化合物的合成方法。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• CONJUGATES COMPRISING A GABA- OR GLYCINE COMPOUND, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS THEREOF AND THEIR USE IN TREATING CNS DISORDERS
  申请人：Nudelman Abraham

  公开号：US20090304584A1

  公开（公告）日：2009-12-10

  Conjugates of a gamma-aminobutyric acid (GABA) compound or a glycine compound and an analgesic drug are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses thereof in the treatment of CNS-associated diseases or disorders, optionally in combination with a psychotropic drug.

  本发明揭示了伽玛-氨基丁酸(GABA)化合物或甘氨酸化合物和镇痛药物的共轭物。此外，还揭示了包含这些共轭物的制药组合物以及在治疗与中枢神经系统相关的疾病或障碍方面的用途，可选择与精神药物联合使用。
• NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS
  申请人：STEIN Gideon

  公开号：US20120277310A1

  公开（公告）日：2012-11-01

  A conjugate comprising L-DOPA covalently linked to at least one γ-aminobutyric acid (GABA) moiety, an ester and/or an addition salt thereof are disclosed, as well as uses thereof for treating a neurodegenerative disease or disorder.

  本发明揭示了一种共轭物，包括L-DOPA与至少一种γ-氨基丁酸（GABA）基团共价连接，以及它的酯和/或加成盐，以及它们在治疗神经退行性疾病或障碍方面的用途。